Standard versus fractionated high dose cisplatin concomitant with radiotherapy in locally advanced head & neck squamous cell cancer (LA-HNSCC): Results of the GORTEC 2015-02 CisFRad randomized trial

0 avis

Standard versus fractionated high dose cisplatin concomitant with radiotherapy in locally advanced head & neck squamous cell cancer (LA-HNSCC): Results of the GORTEC 2015-02 CisFRad randomized trial

Archive ouverte

Edité par CCSD ; Elsevier -

ESMO Virtual Congress, ELECTR NETWORK, SEP 19-OCT 18, 2020. International audience

Langue: en

Consulter en ligne

Consulter le document

Suggestions

Du même auteur

Pembrolizumab versus cetuximab, concomitant with radiotherapy (RT) in locally advanced head and neck squamous cell carcinoma (LA-HNSCC): Results of the GORTEC 2015-01 ``PembroRad'' randomized trial

Archive ouverte | Bourhis, J. | CCSD

ESMO Virtual Congress, ELECTR NETWORK, SEP 19-OCT 18, 2020. International audience

Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial

Archive ouverte | Tao, Y. | CCSD

International audience. To evaluate potential synergistic effect of pembrolizumab with radiotherapy (RT) compared with a standard-of-care (SOC) cetuximab-RT in patients with locally advanced-squamous cell carcinoma ...

3-years follow-up of double-blind randomized phase II comparing concurrent high-dose cisplatin chemo-radiation plus xevinapant or placebo in high-risk patients with locally advanced squamous cell carcinoma of the head and neck

Archive ouverte | Bourhis, J. | CCSD

ESMO Virtual Congress, ELECTR NETWORK, SEP 19-OCT 18, 2020. International audience

Chargement des enrichissements...